AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 82 min read$ANGO

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS

Original reporting
SEC EDGAR 8-K
Published Oct 8, 2026, 11:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ANGO
Bearish
high confidence
Mentioned
$ANGO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ANGOBearishMed
01

Why it matters

The earnings release confirms prior guidance but shows a GAAP loss, which may prompt short‑term selling. However, segment growth and regulatory progress could mitigate downside.

02

Market read

Primary earnings disclosure for a listed med‑tech company; relevance centered on the stock's own performance and guidance.

03

What to watch

The appointment of a new CEO and the FDA IDE approval for the RELIEF study may be catalysts not fully priced yet.

Relevance 7/10Novelty 8/10Timing: today, after the 8‑K release

Background

AngioDynamics (NASDAQ: ANGO) reported FY2027 Q1 results, highlighted Med Tech growth, announced a new CEO, and received FDA IDE approval for a prostate‑hyperplasia study.

Company-level read

Ticker impact

$ANGOBearishHigh confidence
Context

AngioDynamics disclosed its FY2027 Q1 results, including a GAAP loss per share of $0.17, adjusted loss of $0.04, and reaffirmed FY2027 guidance.

Expected impact

likely modest downside as investors price the loss and lack of guidance lift

Evidence & confidence

The 8‑K filing is the first public release of the quarter numbers and guidance; the loss per share and flat outlook suggest limited upside and possible short‑term pressure.

Market effects

Sector

MedTech segment shows double‑digit growth, which may benefit peers in vascular and oncology device space.

Regional

No immediate regional effect beyond the company's own stock.

Global

Limited; the filing is company‑specific.

Counterpoint

What could challenge this read

Despite the loss, the strong Med Tech growth and new FDA IDE approval could support a longer‑term upside.

Key entities

  • company
    AngioDynamics Inc.

    Medical technology firm reporting FY2027 Q1 results.

  • person
    Eric Honroth

    New President and CEO appointed effective Nov 2 2026.

  • regulator
    FDA

    Granted IDE approval for the RELIEF study.

Read at source← All news

Related articles

OCT 8
$ANGOHighAI 8/10

AngioDynamics Q1 FY2027 net loss narrows to $7.1M

AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.

stocktitan.net2 min
OCT 8
$ANGOLow

AngioDynamics, Inc. (ANGO) Appoints Eric Honroth CEO

AngioDynamics, Inc. (ANGO) named Eric Honroth as President and CEO, effective Nov. 2, 2026. He replaces Jim Clemmer, who will leave the board but stay as a consultant. The company aims to advance its transformation and Med Tech momentum under new leadership, according to the press release.

tradingview.com1 min
AUG 11
$ANGOMed

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics (NASDAQ:ANGO) said MedTech is expected to become a majority of revenue by fiscal 2027, citing Auryon share gains and ongoing AMBITION BTK enrollment. Management expects no Auryon study data in fiscal 2027, discussed possible coronary use, and guided fiscal 2027 gross margin to 54% to 55% and adjusted EBITDA to $13M to $16M.

yahoo.com4 min
JUL 21
$ANGOMed

AngioDynamics (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics (ANGO) held its fiscal 2026 Q4 and full-year earnings call. The company said full-year Med Tech growth was over 18% and reported Q4 revenue up 8% to $86.6 million. Q4 Med Tech revenue was $41.8 million (+16.7%). Auryon revenue was $17.8 million (+14.4%). Mechanical thrombectomy revenue was $11.1 million (-1.1%), with AlphaVac up 38.4% and AngioVac down 15.8%. Catalysts include IDE approvals for AlphaReturn and an AngioVac study.

yahoo.com7 min